References
- Yingying Y, Junli Z. Epidemiological characteristics of polycystic ovary syndrome. Chin J Appl Gynecol Obstet. 2019;35(03):1–9.
- Wenming Z, Lingli N, Xiaojuan L. Investigation and analysis of risk factors of polycystic ovary syndrome among women of childbearing age. China Hosp Stat. 2016;23(3):186–189.
- Goodarzi MO, Dumesic DA, Chazenbalk G, et al. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219–231.
- Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–2855.
- Liu Y, Chen Y. Fat mass and obesity associated gene polymorphism and the risk of polycystic ovary syndrome: a meta-analysis. Iran J Public Health. 2017;46(1):4–11.
- Muir AI, Chamberlain L, Elshourbagy NA, et al. AXOR12, a novel human G protein-coupled receptor, activated by the peptide KiSS-1. J Biol Chem. 2001;276(31):28969–28975.
- Trevisan CM, Montagna E, de Oliveira R, et al. Kisspeptin/GPR54 system: what do we know about its role in human reproduction? Cell Physiol Biochem. 2018;49(4):1259–1276.
- Haiyun G, Wei Z. Standardized diagnosis and treatment of polycystic ovary syndrome. Shanghai Med. 2019;40(21):3–6.
- Gottsch ML, Cunningham MJ, Smith JT, et al. A role for kisspeptins in the regulation of gonadotropin secretion in the mouse. Endocrinology. 2004;145(9):4073–4077.
- Navarro VM, Castellano JM, Fernández-Fernández R, et al. Characterization of the potent luteinizing hormone-releasing activity of KiSS-1 peptide, the natural ligand of GPR54. Endocrinology. 2005;146(1):156–163.
- Zarei E, Binabaj MM, Zadeh FM, et al. Kisspeptin levels in relation to sex hormone profile among PCOS patients. Irish J Med Sci. 2022;191(4):1711–1716.
- Jeon YE, Lee KE, Jung JA, et al. Kisspeptin, leptin, and retinol-binding protein 4 in women with polycystic ovary syndrome. Gynecol Obstet Invest. 2013;75(4):268–274.
- Ibrahim RO, Omer SH, Fattah CN. The correlation between hormonal disturbance in PCOS women and serum level of kisspeptin. Int J Endocrinol. 2020;2020:6237141.
- Gorkem U, Togrul C, Arslan E, et al. Is there a role for kisspeptin in pathogenesis ofpolycystic ovary syndrome? Gynecol Endocrinol. 2018;34(2):157–160.
- Wang T, Han S, Tian W, et al. Effects of kisspeptin on pathogenesis and energy metabolism in polycystic ovarian syndrome (PCOS). Gynecol Endocrinol. 2019;35(9):807–810.
- Broekmans FJ, Knauff EA, Valkenburg O, et al. PCOS according to the rotterdam consensus criteria: challenge in prevalence among WHO—II anovulation and association with metabolic factors. BJOG. 2006;113(10):1210–1217.
- Porter JW, Barnas JL, Welly R, et al. Age, sex, and depot-specific differences in adipose-tissue estrogen receptors in individuals with obesity. Obesity (Silver Spring). 2020;28(9):1698–1707.
- Ribeiro AB, Leite CM, Kalil B, et al. Kisspeptin regulates tuberoinfundibular dopaminergic neurones and prolactin secretion in an oestradiol-dependent manner in male and female rats. J Neuroendocrinol. 2015;27(2):88–99.
- Stepto NK, Cassar S, Joham AE, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod. 2013;28(3):777–784.
- Won YB, Seo SK, Yun BH, et al. Non-alcoholic fatty liver disease in polycystic ovary syndrome women. Sci Rep. 2021;11(1):7085.
- Salva-Pastor N, Chávez-Tapia NC, Uribe M, et al. Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease. J Steroid Biochem Mol Biol. 2019;194:105445.
- Lei H, Lei T, Xiaoyong B, et al. Study on the distribution characteristics of abdominal fat in elderly patients with type 2 diabetes and its correlation with metabolic factors. Pract Geriatr. 2018;9:852–855.
- La Marca A, Broekmans FJ, Volpe A, et al. Anti-Mullerian hormone (AMH): what do we still need to know?. Hum Reprod. 2009;24(9):2264–2275.
- Edelsztein NY, Grinspon RP, Schteingart HF, et al. Anti-Mullerian hormone as a marker of steroid and gonadotropin action in the testis of children and adolescents with disorders of the gonadal axis. Int J Pediatr Endocrinol. 2016;2016:20.
- Pellatt L, Rice S, Mason HD. Anti-müllerian hormone and polycystic ovary syndrome: a Mountain too high? Reproduction. 2010;139(5):825–833.
- Huang Chunyue H, Lihui Y, Guang W, et al. Correlation analysis between anti-Miller’s hormone level and metabolic indexes of patients with polycystic ovary syndrome. World Trad Chin Med. 2021;16(14):2171–2176.